RU2400241C1 - Method of obtaining placental medication - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Method of obtaining placental medication on the basis of cows' placenta is characterised by the following: in period of evisceration of incalvers at slaughterhouse, pregnant uterus is removed in the first half of pregnancy (4-5 months), non-separated caruncles and cotyledons are collected from baby's and maternal placenta by cutting cotyledons with curved sterile scissors from baby's placenta, which is made through longitudinal cut in serous-muscular-mucous layer of pregnant uterine horn, puncturing with a needle chorionically amniotic membrane by vacuuming amniotic fluid is collected from amniotic bubble; cut off cotyledond are crushed with caruncles by cutting, after that in mechanical homogeniser, amniotic fluid, previously collected from the same uterus, is added in amount 10:1 of homogenous mass, slowly mixed and settled, after that centrifuged at 10 thousand rev/min for 10 minutes, conservation is performed, supernatant part is poured into vials and sealed.

EFFECT: invention ensures increase of preparation efficiency.

2 tbl

Description

The invention relates to veterinary medicine, in particular to a method for producing a therapeutic tissue preparation from the placenta of agricultural animals.

There is a known method of preparing a preparation from the placenta, when the placenta taken from a cow after cooling and holding in the refrigerator is placed in a special dish made of radiolucent material and treated with microwave radiation with a frequency of 2450 ± 50 MHz used in domestic microwave ovens to separate the liquid component from the tissues of the placenta when heating the raw material is not higher than 60 ° C, and the liquid released during the microwave processing of the raw material is separated from the placental tissue by gravity in an amount of 30 to 60% of the initial mass of the raw material, mixed with a dilution solution and used to prepare a biostimulant (1).

The disadvantage of this method is that natural medicinal cell-produced substances in the form of nanobiological enzymatic and bactericidal models under the influence of microwave radiation and an artificial electric magnetic field with a frequency of 2450 ± 50 MHz at a temperature of + 60 ° C change the biochemical cytomedine structure - a nanoregulatory standard. This reduces the therapeutic effect and monoclonality of antibodies, bactericidal activity, turning the resulting drug into a drug with unknown mutagenic properties. Therefore, for use in the treatment of cows and calves, it may be possible in the future to develop mutagenic dairy and meat products.

There is also a known method for producing the PDE preparation (denatured emulsified placenta), in the manufacture of which the tissues of the infant placenta are used: amniota, chorion tissue (2).

The disadvantage of this method is that upon receipt, chemicals are added to the preparation that lead to changes in the natural properties of protein molecules, nucleic acids, and when the author uses special equipment for dispersion and emulsification, a drop-liquid phase is separated from solutions, which is usually accompanied by a rupture of chemical connections. Therefore, the natural healing properties of the drug are changing, losing the healing bactericidal and stimulating effect.

Closest to the present invention by the technical and biological essence, the achieved result when using is a method for producing medicinal substances from the placenta, including grinding raw materials, conducting weak acid hydrolysis, isolating the product by centrifugation, neutralizing the supernatant, isolating and purifying the drug, freeze-drying (3).

The disadvantage of this invention is that the extraction of biostimulating, therapeutic substances of natural origin under the influence of any degree of acid hydrolysis, as well as sublimation treatment leads to the extraction of a reduced amount or properties of the therapeutic factor.

The objective of the invention is to develop a method for producing a tissue preparation in such ways that would allow nature to extract formulated drugs that have a healing property from the placental tissues of cows in the first half of pregnancy, having bactericidal, bacteriostatic enzymes for use in the treatment of cows with postpartum diseases of the uterus.

The purpose of the invention is to increase the therapeutic and stimulating effectiveness of the drug, made from cotyledon and caruncle placenta taken from pregnant cows.

This goal is achieved in that cotyledons with caruncles taken from the placenta of a pregnant cow in the first half of pregnancy (4-5 months) are rich in natural nanomanipulatory cytomedine medicinal substances since during this period of development of the calf fetus in the amniotic fluid (the product of cotyledons and caruncles) there is a maximum number of bactericidal and bacteriostatic enzymes: lysozyme, compliment, properdine, etc., which are detrimental to microorganisms with one (gram-positive) and two (gram-negative, viruses, fungi ...) membranes.

We collect the united cotyledons with caruncles (they are from 90 to 120 in cows on the placenta) from the placenta from an isolated uterus with fetus taken from the abdominal cavity from healthy pregnant cows in a slaughterhouse as a result of the bankruptcy of the collective farm and cattle farm.

The sequence of the proposed method is as follows:

- the pregnant uterus is removed from the abdominal cavity of the cow in the slaughterhouse during the period of the internship and, for disinfection, it is irrigated with a solution of potassium permanganate 1: 1000;

- a longitudinal section is made on a sterile table with a metal worktop - dissection with a scalpel of the serous-muscular-mucous layers of the large uterine horn (main fetus);

- the suction is evacuated, piercing the amniochorial membrane, through the sterile needle into the glass containers, the contents of the amnion and allantois from the amniotic and allantoic bubbles, leaving the fetus without destroying the unity of the infant and maternal placenta (without disconnecting the cotyledons with caruncles);

- differentiate the suitability of cotyledons and caruncles by integrity, size from fused, pathological;

- collect unconnected cotyledons with caruncles, cutting them off with crooked sterile scissors from the tissues of the baby and mother’s placenta, placing them in sterile glass containers with ground stoppers;

- chopped cut cotyledon with caruncles by grinding, and then in a mechanical homogenizer for 20 minutes at 6 thousand rpm;

- add previously collected from the same uterus settled, filtered, centrifuged amniotic fluid at the rate of 10: 1 homogeneous mass, and all this is slowly mixed for 10 minutes;

- defend for 60 minutes;

- centrifuged at 10 thousand rpm for 10 minutes;

- for conservation, 2 g per 100 ml of boric acid are added to the filtrate;

- the supernatant is poured into bottles with a capacity of 10, 50, 100, 250 cm ³ , corked with rubber stoppers, rolled up with aluminum caps.

The drug is a whitish liquid with a yellowish tint, which meets the requirements for medicinal products.

Practical test of the proposed drug

Many therapeutic substances are present in a living tissue cell. During pregnancy, between the fetal placenta by means of cotyledons and caruncles, there is a connection between the fetal mother and the fetus. In cotyledons and caruncles, there are barrier tissues that not always and not all nutrient, enzymatic, hormonal substances pass through their cell membranes. In the amniotic fluid, in the septa of the villi and crypts, there are a large number of prophylactic and in the nanostate enzymes, especially until the first half of pregnancy. The substances invented by nature in the placenta using the method we offer allow us to isolate both biological active therapeutic substances with the presence of nanoclonal and immune antibodies in the form of nanoregulatory biological models of a personalized direction and stem cells.

The drug in the form of a liquid biostimulator according to A.F. Kolchina and 30% of the ointment of the proposed drug was used in the treatment of cows with postpartum endometritis, as well as in the treatment of guinea pigs with cut and burn wounds of the gluteal muscles.

The results of treatment of animals with the proposed preparations from the carunculo-cotyledon placental tissue and biostimulatory fluid from the placenta (according to A. Kolchina) are shown in Table. 12.

Table 1 The results of the treatment of guinea pigs with wounds and burns A drug Animals were treated (goals) Of them recovered Terms of treatment number % Kotilidonovo-Karunkulovy Cut wounds
8 7 87.5 5 Burn wounds
5 four 80 9 Placental fluid A.F. Kolchina Cut wounds
9 7 77.7 9 Burn wounds
7 5 71,4 eleven

From the table. 1 it can be seen that burn wounds under the influence of the carunculo-cotyledon preparation create a delay, relief and healing in 80% of patients 5 days earlier than in the treatment of burn wounds by A.F. Kolchina's placental fluid (gauze applications and irrigation), i.e. treatment of burn wounds with the proposed drug in the form of 30% ointment after daily lubrication was 8.6% more effective than in the control group of animals. And after the treatment of cut wounds with the proposed drug, the efficiency was higher than in the control by 9.8%.

After a day, sick cows with postpartum cervicitis were injected with 100 ml, 20% carunculo-cotyledon ointment or 100 ml of carunculo-cotyledon liquid preparation in the cervical canal every other day. The results of treatment of cows are shown in table. 2. The control group of cows was injected with furazolidone bacilli into the cervix.

table 2 The effectiveness of the drug in the treatment of cows with cervical inflammation A drug Cows total Of them recovered Recovery time (days) number % Ointment 20% after 24 hours carunculo-cotyledon drug 9 8 88.8 8 Furazolidone sticks (control) 10 8 80 12

From the table. Figure 2 shows that the therapeutic positive effect manifested itself as follows: the carunculo-cotyledon liquid fraction and the therapeutic 20% ointment were 8% more effective than in the control group of sick cows.

References

1. Kolchina A.F. "A method of obtaining a biostimulant from the placenta of cows", patent (RF) RU 2138273 C1.

2. Belyaev V.I., Nezhdanov A.G., Lobodin K.A., Seminikhin I.P., Tyurenkov I.T. “The biological activity of preparations from the placenta”, Veterinary practice, No. 7, 2006, pp. 58-61. Magazine 3.

3. US patent No. 4054648, IPC 6 A61K 35/50. 1977.

Claims (1)

A method of obtaining a placental therapeutic drug based on the placenta of cows, characterized in that during the period of the pregnancy of pregnant cows, a pregnant uterus of healthy cows is removed from the slaughterhouse in the first half of pregnancy (4-5 months), non-separated caruncles and cotyledons are collected from the infant and maternal placenta, cutting cotyledons with curved sterile scissors from the tissue of the baby placenta, performing this through a longitudinal section of the serous-muscular-mucous layer of the pregnant uterine horn, by piercing the chorially amniotic membrane with a needle By ammunition, amniotic fluid is collected from the amniotic bladder, and the cut cotyledones with caruncles are chopped, and then amniotic fluid previously collected from the same uterus is added in a mechanical homogenizer at a rate of 10: 1 of a homogeneous mass, slowly mixed and settled, and then centrifuged at 10 thousand. rpm for 10 min, carry out conservation, the supernatant is poured into vials and sealed.